Journal of Pediatric and Adolescent Gynecology
Volume 24, Issue 2 , Pages 66-70 , April 2011

The Acceptability of Human Papillomavirus Vaccine among Parents and Guardians of Newborn to 10-year-old Children

  • Laura Gillespie, MD

      Affiliations

    • Cleveland Clinic Children’s Hospital, Cleveland, Ohio, USA
    • ,
  • Caitlin W. Hicks, BA

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
    • Corresponding Author InformationAddress correspondence to: Caitlin W. Hicks, BA, 9500 Euclid Ave - NA24, Cleveland, OH 44195; phone: (617) 312-0187; mobile phone: (617) 312-0187; fax: (216) 636-3206.
    • ,
  • Melissa Santana

      Affiliations

    • Hiram College, Cleveland, Ohio, USA
    • ,
  • Sarah E. Worley

      Affiliations

    • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
    • ,
  • David A. Banas, MD

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    • ,
  • Sumayya Holmes

      Affiliations

    • Hampton University, Hampton, Virginia, USA
    • ,
  • Ellen S. Rome, MD, MPH

      Affiliations

    • Cleveland Clinic Children’s Hospital, Cleveland, Ohio, USA

References 

  1. Wetzel C, Tissot A, Kollar LM, et al. Development of an HPV educational protocol for adolescents. J Pediatr Adolesc Gynecol. 2007;20:281
  2. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6
  3. Thompson E. “CDC's human papillomavirus and cervical cancer prevention activities.“ Statement by U.S. Department of Health and Human Services on CDC's Human Papillomavirus (HPV) and Cervical Cancer Prevention Activities. March 3, 2004. http://www.hhs.gov/asl/testify/t040311a.html. Accessed Dec. 13, 2008.
  4. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513
  5. Lowy DR, Solomon D, Hildesheim A, et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008;113:1980
  6. Barr E, Sings HL. Prophylactic HPV vaccines: New interventions for cancer control. Vaccine. 2008;26:6244
  7. Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med. 2008;149:300
  8. US Food and Drug Administration. “FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus.“ FDA News Release June 8, 2006. www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html. Accessed Sept. 22, 2008
  9. Chao C, Slezak JM, Coleman KJ, et al. Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health. 2009;99:1137
  10. Kahn JA, Ding L, Huang B, et al. Mothers intention for their daughters and themselves to receive the human papillomavirus vaccine: A national study of nurses. Pediatrics. 2009;123:1439
  11. Boehner CW, Howe SR, Bernstein DI, et al. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003;30:774
  12. Brabin L, Roberts SA, Farzaneh F, et al. Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes. Vaccine. 2006;24:3087
  13. Davis K, Dickman ED, Ferris D, et al. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188
  14. Rosenthal SL, Rupp R, Zimet GD, et al. Uptake of HPV vaccine: Demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health. 2008;43:239
  15. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: Promise and problems of the magic bullets for prevention and control. Sex Transm Dis. 2000;27:49
  16. Romanowski B, de Borba PC, et al. GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975
  17. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol. 2009;115:S1
  18. Gilbert R, Widom CS, Browne K, et al. Burden and consequences of child maltreatment in high-income countries. Lancet. 2009;373:68
  19. UNESCO Institute for Statistics. Education statistics. 2006;2008(12/13)

PII: S1083-3188(10)00212-3

doi: 10.1016/j.jpag.2010.07.004

Journal of Pediatric and Adolescent Gynecology
Volume 24, Issue 2 , Pages 66-70 , April 2011

Article Tools

* Image Usage & Resolution